Raloxifene improves bone mass in osteopenic women with primary biliary cirrhosis: Results of a pilot study

Liver International

Volumn 25, Issue 1, 2005, Pages 117-121

  Levy, Cynthia ^a,c   Harnois, Denise M ^b   Angulo, Paul ^a   Jorgensen, Roberta ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

Bone disease; Clinical trial; Osteoporosis; Primary biliary cirrhosis; Therapy

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CALCIUM; CREATININE; LIPID; RALOXIFENE; URSODEOXYCHOLIC ACID; VITAMIN D;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BLOOD CELL COUNT; BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FEMUR NECK; FOLLOW UP; HUMAN; LIPID ANALYSIS; LUMBAR SPINE; OPEN STUDY; OSTEOLYSIS; OSTEOPENIA; PILOT STUDY; POSTMENOPAUSE; PRIMARY BILIARY CIRRHOSIS; PROTHROMBIN TIME; RANK SUM TEST; SIDE EFFECT; SINGLE DRUG DOSE; VITAMIN BLOOD LEVEL;

ADMINISTRATION, ORAL; AGED; BONE DENSITY; FEMALE; FEMUR NECK; HUMANS; LIVER; LIVER CIRRHOSIS, BILIARY; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PILOT PROJECTS; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 14544267585     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01026.x     Document Type: Article

References (26)

1. Menon K V, Angulo P, Weston S, et al. Bone disease in primary biliary cirrhosis: independent indicators and rate of progression. J Hepatol 2001; 35: 316-23.
2. Camisasca M, Crosignani A, Battezzati P M, et al. Parenteral calcitonin for metabolic bone disease associated with primary biliary cirrhosis. Hepatology 1994; 20: 633-7.
3. Guanabens N, Pares A, Monegal A, et al. Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: preliminary results after 2 years. Gastroenterology 1997; 113: 219-24.
4. Lindor K D, Janes C H, Crippin J S, et al. Bone disease in primary biliary cirrhosis: does ursodeoxycholic acid make a difference? Hepatology 1995; 21: 389-92.
5. Lindor K D, Jorgensen R A, Tiegs R D, et al. Etidronate for osteoporosis in primary biliary cirrhosis: a randomized trial. J Hepatol 2000; 33: 878-82.
6. Crippin J S, Jorgensen R A, Dickson E R, et al. Hepatic osteodystrophy in primary biliary cirrhosis: effects of medical treatment. Am J Gastroenterol 1994; 89: 47-50.
7. Hulley S, Furberg C, Barrett-Connor E, et al. Non-cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002; 288: 58-66.
8. Pares A, Guanabens N, Ros I, et al. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis (abstract). Hepatology 1999; 30: 472A.
9. Draper M W, Boss S M, Huster W J, et al. Effects of raloxifene hydrochloride on serum markers of bone and lipid metabolism - dose-response relationships (abstract). Calcif Tissue Int 1994; 54: 339.
10. Draper M W, Flowers D E, Huster W J, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11: 835-42.
11. Delmas P D, Bjarnason N H, Mitlak B H, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337: 1641-7.
12. Clemens J A, Bennett D R, Black L J, et al. Effects of a new antiestrogen, keoxifene (LY156758), on growth of carcinogen-induced mammary tumors and on LH and prolactin levels. Life Sci 1983; 32: 2869-75.
13. Anzano M A, Peer C W, Smith J M, et al. Chemoprevention of mammary carcinogenesis in the rat: combined use of raloxifene and 9- cis-retinoic acid. J Natl Cancer Inst 1996; 88: 123-5.
14. Collier J D, Ninkovic M, Compston J E. Guidelines on the management of osteoporosis associated with chronic liver disease. Gut 2002; 50(Suppl. 1): i1-9.
15. Ettinger B, Black D M, Mitlak B H, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999; 282: 637-45.
16. Delmas P D, Ensrud K E, Adachi J D, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002; 87: 3609-17.
17. Sarkar S, Mitlak B H, Wong M, et al. Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy. J Bone Miner Res 2002; 17: 1-10.
18. Bjarnason N H, Sarkar S, Duong T, et al. Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 2001; 12: 922-30.
19. Johnell O, Scheele W H, Lu Y, et al. Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87: 985-92.
20. Taranta A, Brama M, Teti A, et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002; 30: 368-76.
21. Alvaro D, Invernizzi P, Onori P, et al. Expression of estrogen receptors in cholangiocytes of patients with primary biliary cirrhosis (PBC) and relationship with immunohistochemical markers of cell proliferation and death. J Hepatol 2003; 38: 184-5.
22. Alvaro D, Onori P, Metalli V D, et al. Intracellular pathways mediating estrogen-induced cholangiocyte proliferation in the rat. Hepatology 2002; 36: 297-304.
23. Reddy A, Prince M, James O F, et al. Tamoxifen: a novel treatment for primary biliary cirrhosis? Liver Int 2004; 24: 194-7.
24. Invernizzi P, Alvaro D, Crosignani A, et al. Tamoxifen in treatment of primary biliary cirrhosis. Hepatology 2004; 39: 1175-6.
25. Desai P B, Nallani S C, Sane R S, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab Dispos 2002; 30: 608-12.
26. Goodwin B, Redinbo M R, Kliewer S A. Regulation of cyp3a gene transcription by the pregnane x receptor. Annu Rev Pharmacol Toxicol 2002; 42: 1-23.